Curie Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2f Gill St, Woburn, Massachusetts, 01801...Website
www.curietherapeutics.comRevenue
$5.1 MillionIndustry
About Curie Therapeutics
Curie Therapeutics Org Chart
Is Curie Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Curie Therapeutics
Check if Curie Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Curie Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Curie Therapeutics has new funding data
Earning: See what the market has to say on Curie Therapeutics recently announced quarterly report
Click to see if Curie Therapeutics had a recent Job posting/layoffs
Curie Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Curie Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Curie Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Curie Therapeutics
Compare insights from companies similar to Curie Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Curie Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Curie Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Curie Therapeutics.
Curie Therapeutics financials insights
Gather financial insights about Curie Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$75M
Curie Therapeutics Tech Stack
A closer look at the technologies used by Curie Therapeutics
Most Recent Scoops
Curie Therapeutics News & Media
Curie Therapeutics Appoints Georgette Verdin as Chief People Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curie Therapeutics Inc. ("Curie"), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, today announced the appointment of Georgette Verdin as the Company’s Chief People Officer. “Our people are central to achieving our vision of transforming the use of radiopharmaceuticals in oncology. We are invested in and committed to building a culture that values diversity and inclusivity and promotes career devCurie Therapeutics Appoints Karen Smith, M.D., Ph.D., as Independent Board Director
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curie Therapeutics Inc. (“Curie”), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, announced today that it has appointed Karen Smith, M.D., Ph.D., M.B.A., L.L.M., to its Board of Directors. “It is with much excitement that we welcome Karen to our Board of Directors to provide additional diversity of thought and development experience,” said Simon Read, Curie’s CEO and founder. “Karen’s depth of kCurie Therapeutics Expands Radiopharmaceutical Expertise with Appointment of Bernard Lambert, Ph.D. as Chief Technology Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curie Therapeutics Inc. ("Curie"), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, today announced the appointment of Bernard Lambert, Ph.D., as Chief Technology Officer. Dr. Lambert joins Curie Therapeutics to lead the Company’s process development, manufacturing, and technical operations. “I believe that the future success for precision radiopharmaceuticals will be in rationally designed molecuCurie Therapeutics Appoints Kapil Dhingra, MBBS, to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curie Therapeutics Inc. ("Curie"), a biotechnology company focused on developing precision radiopharmaceutical therapies for solid tumors, today announced the appointment of Kapil Dhingra, MBBS, to its Board of Directors. “I am excited to welcome Kapil to our Board of Directors,” said Simon Read, Curie’s CEO and Founder. “Kapil is widely recognized as a thought leader in oncology research and development. His leadership has been key to the approval of a number
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Curie Therapeutics
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radi... Read More